Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Method for replicating influenza virus in culture

A technology of influenza virus and human influenza virus, applied to vaccines for canine respiratory diseases, new immunogenic compositions, and selected in the field of influenza viruses grown in human embryonic kidney cells, can solve the problem of affecting the antigenicity of vaccines, which is difficult to achieve, etc. question

Inactive Publication Date: 2009-12-23
SCHERING PLOUGH ANIMAL HEALTH
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, this approach can be difficult to do and may affect the antigenicity of the resulting vaccine

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for replicating influenza virus in culture
  • Method for replicating influenza virus in culture
  • Method for replicating influenza virus in culture

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0114] Example 1: Chemical reagents and biological reagents

[0115] The infection medium used contains 1L DMEM (Cambrex, catalog number 04-096) or equivalent, stored at 2-7°C; 20mL L-glutamine (Cellgro, catalog number 25-005-CV) or equivalent, stored in -10℃ or lower temperature, once thawed, it can be stored at 2-7℃ for up to 4 weeks; and IX trypsin (Sigma product number T0303, CAS No.9002-07-7) or equivalent, subpackaged And stored frozen at -5 to -30°C. The infection medium is newly prepared before infecting the cells.

[0116] The cell culture medium is prepared as follows: 1 L DMEM, 20 mL L-glutamine, 50 mL fetal bovine serum (Gibco catalog number 04-4000DK) or equivalent (note: from countries without BSE). After preparing the complete medium, store it at 2-7°C for no more than 30 days.

[0117] The EDTA-trypsin (Cellgro catalog number 98-102-CV or equivalent) used for the passage of cells is stored at -5 to -30°C, and the expiry date is indicated by the manufacturer.

Embodiment 2

[0118] Example 2: Cell culture preparation

[0119] Because the protease dilution used in the viral infection step can vary from batch to batch, a new batch of trypsin is titrated before use to establish an optimal level. The example of titration is to serially dilute Type IX trypsin in DMEM containing L-glutamine, and use a semi-logarithmic dilution (10 -1 , 10 -1.5 , 10 -2 , 10 -2.5 Wait). Wash each well of the plate twice with 280 μL of PBS with a 96-well plate containing a single layer of freshly confluent Vero cells. Immediately after washing, add 200 μL of type IX trypsin of each dilution to the plate in a row. Then put the plate at 37°C plus or minus 2°C in 5% CO 2 Incubate in medium and observe the cells 4 days later. The lowest dilution factor of trypsin that shows little or no effect on cell health is selected as the appropriate concentration of trypsin for the isolation and optimization of influenza infection. It is satisfactory and common that there is little or no c...

Embodiment 3

[0126] Example 3: Limiting dilution cloning

[0127] The dilution tube preparation and sample dilution for limiting dilution clones are as follows. Set the test tube (12×75mm) on the test tube rack and label it. One sample is tested per plate, and the dilution series of each sample is 10 -1 To 10 -10 . The diluted medium was dispensed into each test tube in 1.8 mL volume with a serological pipette. The first test tube is labeled Virus Identification. Several other test tubes are prepared to be used as dilution controls and replaced if errors occur during the dilution period. Shake and mix the sample for about 5 seconds, then transfer 200 μL of sample to 10 -1 The dilution tube prepares the initial dilution. Continue to serially dilute to 10 -10 . For each dilution, the sample is mixed by shaking and the pipette tip is changed between dilutions.

[0128] The dilution was transferred to the cell plate as follows. Immediately before use, pour out the culture medium from the cell pl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
lengthaaaaaaaaaa
Login to View More

Abstract

The invention is related to a method for selecting an influenza virus for growth on tissue culture cells to produce a tissue-culture adapted viral isolate. The invention also includes vaccines produced from the isolate.

Description

[0001] Cross-references to related applications [0002] This application claims the priority of US application 60 / 875287 filed on December 15, 2006 and US application 60 / 882412 filed on December 28, 2006, both of which are incorporated herein by reference. technical background [0003] People have known influenza pandemics and pandemics for centuries, and it has caused considerable loss of life. Influenza virus is a segmented RNA-containing virus belonging to the Orthomyxoviridae family. Epidemics and pandemics are caused by viruses with new envelope components that are rarely immune in the population. These new ingredients are usually the result of mutations and / or mixing of human and animal influenza viruses. [0004] However, the capsid of influenza virus is slightly polycrystalline, and its outer surface is the same as that of all viruses. It is composed of a lipid envelope. From the lipid envelope, two prominent glycoprotein spines: hemagglutinin (HA or HA) H) and neuraminida...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/145C12N7/02
CPCC12N2760/16051C12N7/00
Inventor T·L·沃斯梅恩P·高B·A·埃迪O·Y·阿布德尔梅吉
Owner SCHERING PLOUGH ANIMAL HEALTH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com